AKBA is the boswellic acid most studied in boswellia resin research. In rats it suppressed MMP13 and raised the MMP inhibitor TIMP-1.
Also called 3-O-acetyl-11-keto-beta-boswellic acid, acetyl-11-keto-beta-boswellic acid.
AKBA is one of several boswellic acids in the gum resin of Boswellia serrata. Some extracts are standardised to it: 5-Loxin, tested in a 2008 trial, was enriched to 30% AKBA (Sengupta 2008). That paper described AKBA's anti-inflammatory potential as coming through inhibition of the 5-lipoxygenase enzyme (Sengupta 2008).
Its MMP13 evidence comes from a 2025 rat study. Rats had a chemical injected into one knee and were given AKBA by mouth daily from day 3 to day 14. AKBA suppressed MMP13, raised TIMP-1 and the cartilage protein SOX9, lowered blood CTX-II, a type II collagen fragment, and normalised cartilage scores (Abo-Zalam 2025). It also damped the HMGB1, TLR4 and NF-kB inflammatory pathway (Abo-Zalam 2025).
No study on this site measured MMP13 in people taking AKBA. The 30% AKBA extract tested in a human trial was assessed by MMP-3 in joint fluid instead (Sengupta 2008).
In animal and lab studies, yes. AKBA, the lead boswellic acid, suppressed MMP13 in rats with chemically induced knee damage, and a frankincense extract lowered MMP13...
In two main ways. Cells release MMP13 as an inactive proenzyme that must be cut before it works, and the body makes its own inhibitors, the TIMPs. TIMP-1, TIMP-2 and...